Search results
Results From The WOW.Com Content Network
Lercanidipine (trade name Zanidip, among others) is an antihypertensive (blood pressure lowering) drug. It belongs to the dihydropyridine class of calcium channel blockers , which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body.
Calcium channel blocker toxicity is the taking of too much of the medications known as calcium channel blockers (CCBs), either by accident or on purpose. [3] This often causes a slow heart rate and low blood pressure. [1]
The first large study to show a mortality benefit from antihypertensive treatment was the VA-NHLBI study, which found that chlorthalidone was effective. [50] The largest study, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in 2002, concluded that chlorthalidone (a thiazide-like diuretic) was as effective ...
A study in 2000 found that long-term benzodiazepine therapy does not result in brain abnormalities. [75] Withdrawal from high-dose use of nitrazepam anecdotally was alleged in 2001 to have caused severe shock of the whole brain with diffuse slow activity on EEG in one patient after 25 years of use. After withdrawal, abnormalities in hypofrontal ...
A fact from Lercanidipine appeared on Wikipedia's Main Page in the Did you know column on 11 August 2016 (check views). The text of the entry was as follows: The text of the entry was as follows: Did you know ... that grapefruit juice may amplify the antihypertensive effect of lercanidipine ?
Efonidipine is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan.It was launched in 1995, under the brand name Landel (ランデル).The drug blocks both T-type and L-type calcium channels. [1]
It can also be used as a preventative medication in patients over 55 years old to reduce the risk of having a heart attack, stroke or cardiovascular death in patients shown to be at high risk, such as some diabetics and patients with vascular disease. [2] [3] [4] It is a reasonable initial treatment for high blood pressure. [1] It is taken by ...
In large randomized placebo-controlled or active drug-controlled studies conducted in participants with hypertension, stable angina, or type 2 diabetes, long-term treatment with olmesartan has been shown to reduce the levels of markers of vascular inflammation. [18] This effect was also observed in a high-cholesterol primate test model. [19]